MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) - MediciNova (NASDAQ:MNOV) : vimarsana.com

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) - MediciNova (NASDAQ:MNOV)

LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number:

Related Keywords

Tokyo , Japan , Chicago , Illinois , United States , American , Geoff Obrien , Gilbert Youssef , Oncology At Dana Farber Cancer Institute , American Society Of Clinical Oncology , Exchange Commission , Nasdaq , Physician At Harvard Medical School , Medicinova Inc , Standard Market , Tokyo Stock Exchange , Code Number , American Society , Clinical Oncology , Annual Meeting , Attending Physician , Harvard Medical School , Dana Farber Cancer Institute , Rapid Oral Abstract , Central Nervous System , Private Securities Litigation Reform Act ,